Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

SHREVEPORT, La. - The U.S. Department of Health and Human Services has announced $500 million in funding cuts to vaccine ...

Discover Novavax's Q2 2025 earnings insights: raised revenue targets, cost reductions, key partnerships with Sanofi & Takeda, and progress in ...

If you want a COVID-19 shot this fall, will your employer’s health insurance plan pay for it? There’s no clear answer. Health ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda, sending its ...

Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

The company, which is shifting its focus to commercializing vaccine candidates through partnerships, had licensed the rights ...

On a per-share basis, the Gaithersburg, Maryland-based company said it had profit of 62 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

Vinay Prasad is leaving Sensible Medicine to take a senior role at the US FDA. He has our enthusiastic support. Prasad is ...